Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER 2+ breast cancer in Morocco
e13008Background: Trastuzumab (TZM) is available in IV (intravenous) and SC (subcutaneous) formulations in Morocco and is indicated for the treatment of patients with HER 2+ breast cancer. In Morocco, where breast cancer is the most prevalent cancer among women and given the varying healthcare lands...
Saved in:
Published in | Journal of clinical oncology Vol. 43; no. 16_suppl; p. e13008 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
American Society of Clinical Oncology
01.06.2025
|
Online Access | Get full text |
ISSN | 0732-183X 1527-7755 |
DOI | 10.1200/JCO.2025.43.16_suppl.e13008 |
Cover
Summary: | e13008Background: Trastuzumab (TZM) is available in IV (intravenous) and SC (subcutaneous) formulations in Morocco and is indicated for the treatment of patients with HER 2+ breast cancer. In Morocco, where breast cancer is the most prevalent cancer among women and given the varying healthcare landscapes and resource availability from other regions, understanding the comparative costs and logistical implications of these administration routes is crucial. Methods: This is an observational, prospective, multicentre study to analyse cost minimization of IV vs SC TZM treatment in HER 2+ Breast Cancer Patients of Morocco. Participants with histologically confirmed HER 2+ breast cancer between March 2021 and July 2023 were included. The primary endpoint was to compare the average total costs per patient associated with SC versus IV administration of TZM. The secondary endpoint included evaluating the time spent by the patient in the oncology unit and managing any drug-related adverse events related to the IV and SC TZM. Results: In total, 747 patients were recruited from 3 sites in Morocco; 379 patients received IV TZM and 368 received SC TZM. Both groups were similar in terms of average age, weight, cancer histology and monthly income. TZM was given for early breast cancer in 59% of IV and 74% of SC patients, and for metastatic care in 41% of IV and 25% of SC patients. TZM was given as Monotherapy to 44% of patients in the IV group and 83% in the SC group; and in association with chemotherapy to 56% of IV patients and 17% of SC patients; combination therapy included TZM and Pertuzumab in 17% of IV patients and 2% of SC patients. Total direct cost defined as drug, consumable and consultation costs per visit was 4087 Moroccan Dirham (MAD) for IV formulation vs 6258 MAD for SC formulation; p<0.001. The total time from the patient's arrival to departure from the hospital was an average of 220 minutes for IV TZM and 163 minutes for SC TZM; p<0.001. This difference was attributed to patients receiving TZM in monotherapy. Among patients who were administered TZM along with associated Chemotherapy/Pertuzumab: HCP time (Time spent by Physician in explaining, preparation and administration of the drug) was 59 min for IV formulation vs 85 min for SC formulation; p<0.001. It was difficult to evaluate the social impact of the formulation as the majority of women in the sample studied did not work. However, the days of leave among them were significantly lower for the IV formulation than the SC formulation. Conclusions: The study demonstrated that the IV route appears more economically promising than the SC route, with a similar impact on the duration of care and quality of life. This data provides reassurance for a better therapeutic strategy for breast cancer, and they can be used in budgetary impact assessments on the Moroccan population subject to this disease. |
---|---|
Bibliography: | Abstract Disclosures |
ISSN: | 0732-183X 1527-7755 |
DOI: | 10.1200/JCO.2025.43.16_suppl.e13008 |